Stocks
Inhibrx Biosciences, Inc.INBX
NASDAQHealthcareBiotechnology$93.38
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company focused on developing novel biologic therapies for oncology and rare diseases. Its lead candidate, INBRX-101, targets alpha-1 antitrypsin deficiency, and the company has a pipeline of antibody-based therapeutics. Investors track it for its differentiated approach to protein engineering and potential regulatory milestones.
52W Range: $46.01-$155.29
Congressional Interest in Inhibrx Biosciences, Inc. (INBX)
No congressional trades have been disclosed for Inhibrx Biosciences, Inc. (INBX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading INBX?
No congressional trades found for this stock.